![]() |
![]() |
Legal status
Patent not validated
(51) | INT.CL. | A61K 45/06 | (2013.01) |
A61K 31/365 | (2006.01) | ||
A61K 31/404 | (2006.01) | ||
A61K 31/553 | (2013.01) | ||
A61K 31/53 | (2013.01) | ||
A61K 31/437 | (2006.01) | ||
A61K 31/551 | (2013.01) | ||
A61K 31/44 | (2006.01) | ||
A61K 31/5377 | (2013.01) | ||
A61K 31/444 | (2006.01) | ||
A61K 31/4709 | (2006.01) | ||
A61K 31/404 | (2013.01) | ||
A61K 31/496 | (2006.01) | ||
A61K 31/44 | (2013.01) | ||
A61K 31/497 | (2006.01) | ||
A61K 31/4709 | (2013.01) | ||
A61K 31/444 | (2013.01) | ||
A61K 31/5025 | (2006.01) | ||
A61K 31/365 | (2013.01) | ||
A61K 31/53 | (2006.01) | ||
A61K 31/497 | (2013.01) | ||
A61K 31/5377 | (2006.01) | ||
A61K 31/5025 | (2013.01) | ||
A61K 31/551 | (2006.01) | ||
A61K 31/496 | (2013.01) | ||
A61K 31/553 | (2006.01) | ||
A61K 31/437 | (2013.01) | ||
A61K 45/06 | (2006.01) | ||
C07D 251/52 | (2013.01) | ||
A61K 9/00 | (2006.01) | ||
C07D 403/14 | (2013.01) | ||
A61P 35/00 | (2006.01) | ||
C07D 401/14 | (2013.01) | ||
A61P 35/02 | (2006.01) | ||
A61P 35/02 | (2018.01) | ||
C07D 251/52 | (2006.01) | ||
C07D 401/14 | (2006.01) | ||
C07D 403/14 | (2006.01) |
(11) | Number of the document | 3419593 |
(13) | Kind of document | T |
(96) | European patent application number | 16816810.2 |
Date of filing the European patent application | 2016-12-02 | |
(97) | Date of publication of the European application | 2019-01-02 |
(45) | Date of publication and mention of the grant of the patent | 2022-03-23 |
(46) | Date of publication of the claims translation |
(86) | Number | PCT/US2016/064615 |
Date | 2016-12-02 |
(87) | Number | WO 2017/146794 |
Date | 2017-08-31 |
(30) | Number | Date | Country code |
201662300673 P | 2016-02-26 | US |
(72) |
AMATANGELO, Michael , US
HU, Xiaolan , US
THAKURTA, Anjan , US
CHOE, Sung Eun , US
WU, Bin , US
|
(73) |
Celgene Corporation ,
86 Morris Avenue, Summit, NJ 07901,
US
Les Laboratoires Servier , 50 rue Carnot, 92284 Suresnes Cedex, FR |
(54) | ENASIDENIB FOR USE IN THE TREATMENT OF RELAPSED OR REFRACTORY ACUTE MYELOID LEUKAEMIA |
ENASIDENIB FOR USE IN THE TREATMENT OF RELAPSED OR REFRACTORY ACUTE MYELOID LEUKAEMIA |